Figure 5: MBH oleic acid and a DVC NMDA receptor-dependent mechanism.

(a) Experimental protocol: stereotaxic placement of cannulae into both the MBH and DVC. DVC preinfusions of saline or MK-801 were commenced at t=−20 min and simultaneous MBH infusions of vehicle or oleic acid were commenced at t=−10 min. (b) Plasma TG concentrations and (c) rates of appearance of VLDL-TG in plasma following MBH infusion of vehicle and concurrent DVC infusion of saline or MK-801 (white open squares, n=10 comprised of n=5 DVC saline and n=5 DVC MK-801) or MBH of oleic acid and concurrent DVC infusion of saline (black squares, n=7) or MK-801 (grey squares, n=7). *P<0.02; versus other groups. (d) Plasma TG concentrations and (e) rates of appearance of VLDL-TG in plasma following MBH infusion of vehicle and concurrent DVC infusion of saline (white open squares, n=5) or DVC glycine (grey circles, n=7) or MBH infusion of oleic acid with concurrent DVC infusion of saline (black squares, n=7) or DVC glycine (grey triangles, n=6). *P<0.05; versus MBH vehicle+DVC saline. Data are presented as mean+s.e.m. Statistical significance determined by Dunnett’s post hoc test after analysis of variance (ANOVA). For measurements over time, repeated measures ANOVA was used followed by Duncan’s post hoc test.